0 4 8 12 16 20 24 28 32 36 40 44 48 -250 -200 -150 -100 -50 0 Aflibercept Q8W (n=281) Tarcocimab Q4W (n=276) Week μm In DAYBREAK for wet AMD, what are the potential implications and upsides for tarcocimab? • Topline data expected Q3 2026 • If successful, DAYBREAK will demonstrate tarcocimab’s (commercial formulation) ability to provide: • Strong and immediate disease control in the loading phase (closing the ‘immediacy gap’), • Non-inferior vision gains to aflibercept Q8W, and • Long-interval dosing with a flexible 1-month through 6-month label Illustrative only : Highlighting the potential for the tarcocimab commercial formulation to demonstrate high immediacy (in the loading phase) and high durability (in the maintenance phase) Strong disease control Majority of patients maintain drying effect with long-interval dosing vs Q8W aflibercept Topline data: Q3 2026 Noninferiority study 6-month durability Wet AMD DAYBREAK 37 Quadrant of core unmet need